Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Canther logo — “CANcer Heterogeneity, Plasticity and Resistance to THERapie...

Canther

“CANcer Heterogeneity, Plasticity and Resistance to THERapies”

Founded 2020 France France 39 employees Health Care

General Information

Company Name Canther
Founded Year 2020
Location France France +1
Employees 39
Industries Health Care
Social

Get notified when Canther moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Canther

Canther is a research laboratory focused on “CANcer Heterogeneity, Plasticity and Resistance to THERapies”, established in 2020. It operates as a collaboration between the University of Lille, CNRS, Inserm, Lille University Hospital (CHU Lille), Lille Pasteur Institute (IPL), Cancer Centre Oscar Lambret (COL), and Lille Research Institute against Cancer (IRCL). The lab comprises five teams, each specializing in unique mechanisms related to cancer research. Dr. Isabelle Van Seuningen's team focuses on resistance to chemotherapies, Dr. David Tulasne's team studies resistance to targeted therapies, Pr Bruno Quesnel's team specializes in tumor dormancy in leukemias, Pr Corinne Abbadie's team explores senescence and fibrosis mechanisms associated with cancer, and Pr Xuefen Le Bourhis's team delves into mechanisms of resistance associated with the metastatic process. Canther operates within the Health Care industry and despite the lack of disclosed information regarding its headquarters, recent investments, and investors, its collaborative structure and focus on cancer resistance mechanisms make it a promising venture in the field of cancer research and therapy.

Taxonomy: Cancer research, University collaboration, Chemotherapy resistance, Targeted therapy resistance, Tumor dormancy, Leukemia research, Senescence, Fibrosis, Metastasis resistance, Multidisciplinary approach

No funding data available for Canther yet.

Get notified when Canther raises funding

Canther Alternatives & Competitors

Canther vs
Kurome Therapeutics, Inc.
Kurome Therapeutics, Inc. United States

A preclinical stage company focused on subverting cancer's ability to evade therapy.

Series A
6 employees
Biotechnology, Health Care
Canther vs
BioVersys AG
BioVersys AG Switzerland

Leadership in overcoming the antibiotic resistance crisis.

Series C
27 employees
Biotechnology, Pharmaceutical
Canther vs
Arrevus
Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.

Grant
Biotechnology, Pharmaceutical

FAQ About Canther

“CANcer Heterogeneity, Plasticity and Resistance to THERapies”
Canther was founded in 2020.
Canther is headquartered in France.
Canther operates in the following industries: Health Care.
Canther has approximately 39 employees.
Top alternatives and competitors to Canther include Kurome Therapeutics, Inc., BioVersys AG, Arrevus, ORIC Pharmaceuticals Inc., Navire Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Canther and Kurome Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Canther and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy